Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Pilot Study of Post-transplant High Dose Cyclophosphamide (PTCY) as Part of Graft-Versus-Host Disease (GVHD) Prophylaxis in T-Cell Replete HLA-Mismatched Unrelated Donor (MMUD) Ablative and Reduced Intensity Hematopoietic Cell Transplantation (HCT) for Hematological Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03128359
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:22.542450+00:00
Published At
2023-06-09T00:00:00+00:00
Record Updated At
2024-01-09
Results Posted At
2023-06-09
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Acute Leukemia", "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Diffuse Large B-Cell Lymphoma", "Follicular Lymphoma", "Graft Versus Host Disease", "Hodgkin Lymphoma", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Myelodysplastic Syndrome", "Myeloproliferative Neoplasm", "Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes", "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma", "Secondary Myelodysplastic Syndrome"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-01-09"
protocolSection.identificationModule.nctId
"NCT03128359"
protocolSection.identificationModule.officialTitle
"A Pilot Study of Post-transplant High Dose Cyclophosphamide (PTCY) as Part of Graft-Versus-Host Disease (GVHD) Prophylaxis in T-Cell Replete HLA-Mismatched Unrelated Donor (MMUD) Ablative and Reduced Intensity Hematopoietic Cell Transplantation (HCT) for Hematological Malignancies"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2023-06-09"

Study condition terms

  • Acute Leukemia (protocolSection.conditionsModule.conditions)
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (protocolSection.conditionsModule.conditions)
  • Chronic Myelogenous Leukemia, BCR-ABL1 Positive (protocolSection.conditionsModule.conditions)
  • Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Graft Versus Host Disease (protocolSection.conditionsModule.conditions)
  • Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Mantle Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Marginal Zone Lymphoma (protocolSection.conditionsModule.conditions)
  • Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
  • Myeloproliferative Neoplasm (protocolSection.conditionsModule.conditions)
  • Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes (protocolSection.conditionsModule.conditions)
  • Recurrent Plasma Cell Myeloma (protocolSection.conditionsModule.conditions)
  • Refractory Plasma Cell Myeloma (protocolSection.conditionsModule.conditions)
  • Secondary Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.